Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe
This article was originally published in PharmAsia News
Executive Summary
Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with U.S. FDA